Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
by on Wednesday, February 8th, 2012 | No Comments
Condition: Metastatic Breast Cancer
Interventions: Drug: TKI258 (Dovitinib); Device: Fulvestrant
Sponsor: Novartis Pharmaceuticals
Not yet recruiting – verified February 2012
Excerpt from: Trial Evaluating TKI258 Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer